Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recen ...

"Prostate cancer is a worldwide problem. It is the most common cancer in men, with clear racial disparities,” said researcher ...

Dsicover a recent study that compared Stockholm3 with other established biomarkers for prostate cancer screening. Learn more.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: ...

A biomarker, PROSTOX, predicted late genitourinary toxicity accurately in patients with prostate cancer, yielding an area under the curve of 0.76.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management ...

The breakthrough blood test uses AI to detect the 12 most lethal and common cancers from an mRNA signature which shows if ...